LAVA Therapeutics NV (LAVA Therapeutics NV) EBIT : $-29.88 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is LAVA Therapeutics NV EBIT?

LAVA Therapeutics NV's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-1.95 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-29.88 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. LAVA Therapeutics NV's annualized ROC % for the quarter that ended in Mar. 2024 was -103.90%. LAVA Therapeutics NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -335.90%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. LAVA Therapeutics NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 107.83%.

LAVA Therapeutics NV EBIT Historical Data

The historical data trend for LAVA Therapeutics NV's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LAVA Therapeutics NV EBIT Chart

LAVA Therapeutics NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

-9.60

-15.54

-41.57

-31.58

-41.46

LAVA Therapeutics NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial													-13.54	-13.55	-10.73	-3.65	-1.95

Competitive Comparison of LAVA Therapeutics NV's EBIT

For the Biotechnology subindustry, LAVA Therapeutics NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LAVA Therapeutics NV's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LAVA Therapeutics NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where LAVA Therapeutics NV's EV-to-EBIT falls into.

LAVA Therapeutics NV EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.88 Mil.

LAVA Therapeutics NV (NAS:LVTX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

LAVA Therapeutics NV's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-7.808 * ( 1 - -14.26% )	/	( (9.017	+	8.156)	/ 2 )
=	-8.9214208	/	8.5865
=	-103.90 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	101.71	-	8.737	-	( 95.571	-	max(0, 14.941	-	98.897	+	95.571	))
=	9.017

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	99.079	-	7.282	-	( 94.573	-	max(0, 13.027	-	96.668	+	94.573	))
=	8.156

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

LAVA Therapeutics NV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-7.808	/	( ( (2.494 + max(-6.133, 0))	+	(2.155 + max(-5.357, 0)) )	/	2 )
=	-7.808	/	( ( 2.494	+	2.155 )	/	2 )
=	-7.808	/	2.3245
=	-335.90 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.459	+	0	+	1.627)	-	(8.737	+	0	+	0.482)
=	-6.133

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.737	+	0	+	1.188)	-	(7.282	+	0	+	-1.7763568394003E-15)
=	-5.357

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

LAVA Therapeutics NV's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-29.876	/	-27.706
	=	107.83 %

LAVA Therapeutics NV EBIT Related Terms

Thank you for viewing the detailed overview of LAVA Therapeutics NV's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

LAVA Therapeutics NV (LAVA Therapeutics NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

4PKB:Germany

Address

Yalelaan 62, Utrecht, UT, NLD, 3584 CM

Website

https://www.lavatherapeutics.com

LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.